Vera Therapeutics
VERA
70 hedge funds and large institutions have $290M invested in Vera Therapeutics in 2023 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 9 closing their positions.
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
21% more funds holding
Funds holding: 58 → 70 (+12)
11.98% more ownership
Funds ownership: 77.08% → 89.07% (+12%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less capital invested
Capital invested by funds: $413M → $290M (-$123M)
41% less call options, than puts
Call options by funds: $185K | Put options by funds: $314K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$22.8M |
| 2 |
CC
Commodore Capital
New York
|
+$21.8M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$15.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.7M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.38M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.75M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.51M |
| 4 |
Walleye Capital
New York
|
-$1.69M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$880K |
VERA Hedge Fund Activity: Q1 2023 in Review
70 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q1 2023, worth a combined $290M — down 30% from $413M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VERA positions and 9 closed out — a net gain of 13 holders — while 29 added to existing stakes and 10 trimmed.
The largest buyer was Carlyle Group, opening a new position worth an estimated $22.8M. The largest seller was Citadel Advisors, cutting an estimated $9.38M.
- 70 institutional investors held Vera Therapeutics (VERA) as of Q1 2023, up from 58 in Q4 2022.
- Funds reported $290M of Vera Therapeutics stock for Q1 2023, down 30% quarter-over-quarter.
- 22 funds opened new Vera Therapeutics positions in Q1 2023 and 9 closed out, a net change of +13 holders.
- The largest Vera Therapeutics buyer in Q1 2023 was Carlyle Group, an estimated $22.8M added.
- The largest Vera Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $9.38M sold.
Based on aggregated 13F filings for Q1 2023.